Glaxosmithkline Pharmaceuticals Ltd

Y/e 31 Mar( In .Cr)	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Equity Capital	169.41	169.41	169.41	169.41
Preference Capital	0	0	0	0
Reserves	1,614.69	1,583.59	2,508.21	1,327.71
Net Worth	1,784.1	1,753	2,677.62	1,497.12
Minority Interest

Y/e 31 Mar( In .Cr)	Mar-2022	Mar-2021	Mar-2020	Mar-2018
Revenue	3,217.5	2,920.47	3,224.68	2,871.68
yoy growth (%)	10.17	-9.43	12.29	-1.07
Raw materials	-1,295.73	-1,249.36	-1,307.86	-1,240.75
As % of sales	40.27	42.77	40.55	43.2
Employee costs	-610.23	-616.16	-628.55	-523.39

Y/e 31 Mar( In .Cr)	Mar-2022	Mar-2021	Mar-2020	Mar-2018
Profit before tax	761.86	625.82	646.99	523.78
Depreciation	-68.18	-78.6	-82.67	-37.98
Tax paid	-396.86	-166.53	-212.44	-189.59
Working capital	776.94	111.42	187.45	-365.58
Other operating items

Y/e 31 Mar	Mar-2022	Mar-2021	Mar-2020	Mar-2018
Growth matrix (%)
Revenue growth	10.17	-9.43	12.29	-1.07
Op profit growth	26.44	-9.21	29.5	21.07
EBIT growth	21.37	-3.66	24.68	12.53
Net profit growth	372.78	224.9	-68.73	4.51

Particulars (Rupees in Crores.)	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Gross Sales	3,453.71	3,251.72	3,278.03	2,925.6	3,224.38
Excise Duty	0	0	0	0	0
Net Sales	3,453.71	3,251.72	3,278.03	2,925.6	3,224.38
Other Operating Income	0	0	0	0	0
Other Income	122.59	103.71	1,401.31	181.46	79.01

Company Name	LTP (₹)	P/E (%)	Mkt.Cap (₹Cr.)	NP Qtr (₹Cr.)	Div.Yield (%)	Sales Qtr (₹.Cr)	Book Value (₹)
Sun Pharmaceuticals Industries Ltd SUNPHARMA	1,568.65	123.31	3,76,323.69	867.6	0.86	5,536.99	98.75
Divis Laboratories Ltd DIVISLAB	4,519.8	76.17	1,19,994.45	531	0.66	2,259	507.93
Cipla Ltd CIPLA	1,485.5	32.29	1,19,928.54	1,038.4	0.57	3,444.92	346.41
Zydus Lifesciences Ltd ZYDUSLIFE	1,144.45	33.51	1,15,173.54	1,405.2	0.26	3,172.6	156.19
Dr Reddys Laboratories Ltd DRREDDY	6,636	25.85	1,10,759.07	1,034.8	0.6	5,081.8	1,458.96

Derivatives

IPO

Mutual Funds

Nifty 50

Loans

Knowledge Center

News

IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

Derivatives

IPO

Mutual Funds

Nifty 50

Loans

Knowledge Center

News

Disclaimer

Research Disclaimer

Twitter Disclaimer

Terms & Conditions

RBI Policy Update

CSR Policy

Sitemap

ATTENTION INVESTORS

Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to Rs. 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

Glaxosmithkline Pharmaceuticals Ltd Share Price

Invest wise with Expert advice

Equities

Futures

Option